- Home
- ZDAI vs BIAF Comparison
ZDAI vs BIAF Comparison
Compare ZDAI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZDAI | BIAF |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.8M |
| IPO Year | 2024 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ZDAI | BIAF |
|---|---|---|
| Price | $0.58 | $1.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 307.3K | 80.0K |
| Earning Date | 02-03-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,141,479.00 | $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $1.11 |
| 52 Week High | $1.17 | $46.53 |
Technical Indicators
Market Signals| Indicator | ZDAI | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 50.64 |
| Support Level | $0.42 | $1.26 |
| Resistance Level | $0.65 | $1.44 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 81.55 | 58.30 |
Price Performance
Historical ComparisonAbout ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.